{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2024.07.11.24310105v2\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2024.07.11.24310105v2\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2024.07.11.24310105v2\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAbstract\u003C\/h2\u003E\u003Cdiv id=\u0022sec-1\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-3\u0022\u003E\u003Cstrong\u003EBackground\u003C\/strong\u003E Despite chemo-immunotherapy has been applied to the neoadjuvant treatment of non-small cell lung cancer (NSCLC), the impacts of dosage and the order of medication on treatment efficacy and safety remain largely unexplored. We originally designed an exploratory study to investigate the efficacy and safety of reduced-dose chemotherapy combined with delayed immunotherapy as well as the dynamic changes of circulating tumor DNA (ctDNA) and T cell receptor (TCR) during the therapy.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-2\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-4\u0022\u003E\u003Cstrong\u003EMethods\u003C\/strong\u003E Patients with clinical stage IIA to IIIA resectable NSCLC were treated with 2 cycles of reduced-dose platinum-based chemotherapy on day 1 combined with immunotherapy on day 5. The same postoperative modified adjuvant therapy regimen was administered for 2 cycles. Plasma samples at different time-points were collected and performed with T cell receptor (TCR) and circulating tumor DNA (ctDNA) sequencing.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-5\u0022\u003E\u003Cstrong\u003EResults\u003C\/strong\u003E 38 patients received modified chemo-immunotherapy. The proportion of patients exhibiting complete response and partial response was 5.3% and 68.4%, respectively. The confirmed objective response rate was 73.7%. Radiological downstaging was achieved in 39.5%. Major pathologic response and complete pathologic response were observed in 47.4% and 31.6% of patients, respectively. Only one patient experienced grade 3 adverse event. Further analyses revealed that this modified chemo-immunotherapy led to the expansion of predominant TCR clones and reduction of tumor burden after the first cycle of chemotherapy.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-6\u0022\u003E\u003Cstrong\u003EConclusion\u003C\/strong\u003E The promising clinical efficacy and low side effects of modified neoadjuvant chemo-immunotherapy position it as a prospective and innovative strategy for NSCLC.\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003E\u003Cstrong\u003ETrial registration:\u003C\/strong\u003E Registration Number: ChiCTR2000033092\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-5\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EBackground\u003C\/h2\u003E\u003Cp id=\u0022p-22\u0022\u003EApproximately 20 to 25% of patients diagnosed with NSCLC are eligible for surgical resection (\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E), yet 30% to 55% of those who undergo curative surgery will encounter recurrence and ultimately die (\u003Ca id=\u0022xref-ref-2-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E). Despite the improvement in treatment of NSCLC patients, the 5-year survival rates remain relatively low, hovering around 36% (\u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E). Over the past decade, neoadjuvant platinum-based chemotherapy, followed by surgery, has become the standard of care. Nevertheless, only 5 to 6 % improvements have been noted in 5-year recurrence-free survival and overall survival rates compared to surgery alone (\u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-23\u0022\u003ECurrently, combination of chemotherapy with immunotherapy has demonstrated superior clinical efficacy and prolonged event-free survival for patients with resectable NSCLC. Trials such as CheckMate 816 (\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E), SAKK 16\/14 (\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E), and NADIM (\u003Ca id=\u0022xref-ref-8-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E), have showcased the enhanced efficacy and manageable safety of combination therapy compared to monotherapy. However, for most previous clinical trials, cytotoxic drugs with standard doses and anti-PD1 antibody were administrated on the same day (\u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E), which may result in unsatisfactory eradication rates and relatively high incidence of severe treatment-related adverse events (TRAEs). To improve the cure rate and reduce TRAEs, the use of low-dose chemotherapy may represent a feasible alternative, given it favorable tolerability profile without compromising efficacy (\u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E). Although various regimens of low-dose chemotherapy have been utilized in cancer therapy (\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E), the effects of dosage and administration sequence on the efficacy and safety of NSCLC treatment remain controversial. According to our previous research findings, the administration of immunotherapy 3-5 days after chemotherapy significantly reduces lymphocyte damage (\u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E). Therefore, we hypothesize that by coordinating the dosage of chemotherapy and the timing of immunotherapy administration, we can enhance the synergistic effects between the two interventions. Ultimately, this could improve clinical efficacy while reducing toxic side effects.\u003C\/p\u003E\u003Cp id=\u0022p-24\u0022\u003ETo monitor the therapeutic efficacy during the process of chemo-immunotherapy, there is an urgent requirement for reliable indicators. The T cell receptor (TCR) repertoire and the presence of circulating tumor DNA (ctDNA) in blood have been proven to be efficient predictors of therapeutic responses in cancer treatment (\u003Ca id=\u0022xref-ref-15-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-16-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E). Chemotherapeutic agents have the capability to induce immunogenic death of tumor cells, reduce tumor burden, and promote the infiltration of CD8 T lymphocyte (\u003Ca id=\u0022xref-ref-17-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-18-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E). The recognition of tumor antigens by CD8 T lymphocytes relies primarily on the presence of a diverse and polymorphic TCR within an individual (\u003Ca id=\u0022xref-ref-19-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E). Hence, it is imperative to explore the dynamic changes of TCR diversity and tumor burden in ctDNA throughout the course of therapy.\u003C\/p\u003E\u003Cp id=\u0022p-25\u0022\u003EIn this study, we report the results of our pilot clinical trial assessing the efficacy and safety of modified neoadjuvant chemo-immunotherapy in patients with resectable NSCLC. These results indicate that the combination of low-dose chemotherapy followed by delayed immunotherapy could potentially induce tumor cell damage, promote antigen exposure, and support T cell expansion, thereby enhancing therapeutic efficacy and reducing toxic side effects. Monitoring the dynamic changes of TCR repertoire and ctDNA does not only offer insights into the mechanism underlying our therapeutic approach to some extent but also furnishes valuable data for monitoring treatment efficacy.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-6\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EMaterials and Methods\u003C\/h2\u003E\u003Cdiv id=\u0022sec-7\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStudy design and participants\u003C\/h3\u003E\u003Cp id=\u0022p-26\u0022\u003E38 Patients with resectable stage IIA to IIIA NSCLC, as per the staging criteria outlined by the American Joint Committee on Cancer, 8th edition, and possessing adequate organ function, along with an Eastern Cooperative Oncology Group performance-status rating of 0 to 1, were included in this study. All patients had not received any prior cancer treatment, exhibited measurable disease according to the Response Evaluation Criteria in Solid Tumors (version 1.1) and had confirmed histological or cytological evidence of the disease. Exclusion criteria included the presence of identified \u003Cem\u003EEGFR\u003C\/em\u003E mutations or \u003Cem\u003EALK\u003C\/em\u003E translocations; a diagnosis of malignancies beyond NSCLC within 5 years; previous exposure to specific therapies such as anti-PD-1, anti-PD-L1, or anti-PD-L2 agents or medications targeting T cell receptor modulation (e.g., CTLA-4, LAG-3, or TIM-3); a history of allogeneic organ or hematopoietic stem cell transplantation (except corneal transplantation); ongoing repercussions from prior interventions; pregnancy or breastfeeding; and HIV positivity. Moreover, the availability of pre- and post-adjuvant treatment tumor tissues and serial blood samples facilitated comprehensive analyses including whole transcriptome sequencing, TCR sequencing, and ctDNA sequencing.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ETrial design and treatment\u003C\/h3\u003E\u003Cp id=\u0022p-27\u0022\u003EThis study was a single-center, single-arm, pilot clinical trial (Registration Number: ChiCTR2000033092). Eligible patients received 2 cycles of neoadjuvant therapy of low-dose platinum-based chemotherapy: albumin-bound paclitaxel 180-220 mg\/m\u003Csup\u003E2\u003C\/sup\u003E plus cisplatin 60 mg\/m\u003Csup\u003E2\u003C\/sup\u003E for lung squamous cell carcinoma or pemetrexed disodium 500 mg\/m\u003Csup\u003E2\u003C\/sup\u003E plus cisplatin 60 mg\/m\u003Csup\u003E2\u003C\/sup\u003E for lung adenocarcinoma respectively on day 1 plus sintilimab 200 mg on day 5 of each cycle, followed by radiographic evaluation before undergoing radical surgery. Surgery was conducted within 6 weeks after the completion of neoadjuvant treatment. Then patients would receive 2 cycles of adjuvant therapy with the same regimen.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStudy outcomes\u003C\/h3\u003E\u003Cp id=\u0022p-28\u0022\u003EThe primary endpoints include objective response rate (ORR: the proportion of patients with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors) and major pathologic response (MPR) (less than 10% residual viable tumor cells in the primary tumor and sampled lymph nodes) according to the pathologist review. Secondary endpoint included pathologic complete response (pCR) (0% residual viable tumor cells in the primary tumor and sampled lymph nodes), disease free survival (DFS), treatment-related adverse events (TRAEs), occurrence of surgical complications, and intraoperative and perioperative complications.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-10\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPlasma collection, cell-free DNA extraction, and sequencing\u003C\/h3\u003E\u003Cp id=\u0022p-29\u0022\u003EBlood samples were collected into cell-free DNA blood streck tubes. Isolated plasma and paired white blood cell (WBC) control were stored at -80 until extraction. Cell-free DNA (cfDNA) and WBC-derived DNA were extracted from 4 mL plasma and WBC using QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) and Mag-Bind\u00ae Blood \u0026amp; Tissue DNA HDQ 96 kit (OMEGA) according to the manufacturer\u2019s instructions, respectively. DNA extracts were sheared to 100 bp fragments using an S220 focused ultrasonicator (Covaris, Woodbrun, MA, USA). The adaptors (NadPrep\u00ae) were attached to the terminal of fragments and followed by PCR (Bio-Rad T100, USA) replication. The libraries were constructed using NadPrep Plasma Cell-Free DNA Dual-Ended Molecular Tag Library Construction Kit (for MGI) (Nanodigmbio). The target customized probes YuceOne Plus (ctDNA) synthesized by IDT were used for hybridization enrichment. Target enrichment was performed with NadPrep Hybrid Capture Reagents (Nanodigmbio). The enriched DNA fragments were sequenced with the MGISEQ platform. The mean depth of coverage was 3445\u00d7 for cfDNA and 1419\u00d7 for matched peripheral blood samples.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-11\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ECirculating tumor DNA (ctDNA) analysis\u003C\/h3\u003E\u003Cp id=\u0022p-30\u0022\u003ESOAPnuke was implemented to cut the adapter and remove low-quality raw reads (\u003Ca id=\u0022xref-ref-20-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003E20\u003C\/a\u003E). Genecore was performed for cluster reads by unique molecule index (UMI) and remove the replicated reads derived from PCR (\u003Ca id=\u0022xref-ref-21-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003E21\u003C\/a\u003E). Clean reads were aligned against the human reference genome (hg19) with BWA (v0.7.12) (\u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E) and duplicated reads were removed by samtools (v0.1.19) (\u003Ca id=\u0022xref-ref-23-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E). Subsequently, generated BAM files were used for downstream analysis. We compared the ctDNA samples and matched control blood sequencing data to identify the somatic mutations, including single nucleotide variants (SNVs) and small insertions and deletions (Indels) using mutation caller Vardict (v1.7.0) with default parameters (\u003Ca id=\u0022xref-ref-24-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003E24\u003C\/a\u003E). Next, the caller was run with dbSNP (version 147), 1000G (phase3_release_v5), CLINVAR (version 151 ClinVar (\u003Ca href=\u0022https:\/\/nih.gov\u0022\u003Enih.gov\u003C\/a\u003E)), and COSMIC (version 81) data for known polymorphic sites. Substitutions and indels would be filtered out according to the following criteria: 1) low variant allelic fractions (VAF \u0026lt; 0.0005), 2) removed any variants with greater than 1 supporting read in the matched germline sample, 3) variants present in the above genome database. In addition, the filtered mutations were annotated by snpEff (v4.3) (\u003Ca id=\u0022xref-ref-25-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-25\u0022\u003E25\u003C\/a\u003E) with NCBIrefseq (\u003Ca href=\u0022https:\/\/www.ncbi.nlm.nih.gov\/refseq\/\u0022\u003Ehttps:\/\/www.ncbi.nlm.nih.gov\/refseq\/\u003C\/a\u003E). The maximum VAF is considered as the tumor burden during the therapy.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-12\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EWhole transcriptome sequencing\u003C\/h3\u003E\u003Cp id=\u0022p-31\u0022\u003EThe total RNA of tumor samples was isolated using the RNeasy FFPE Kit (Qiagen, GER) according to the manufacturer\u2019s instructions. The concentrations of RNA were quantified using Qubit\u2122 RNA HS Assay Kit (ThermoFisher Scientific, USA). RNA purity and integrity were checked using the Take3 (BioTek, USA) and the RNA Cartridge kit of the Qseq100 Bio-Fragment Analyzer (Bioptic, CHN), respectively. Then, RNA sequencing (RNA-seq) libraries were constructed using the rRNA depletion module (H\/M\/R) and NadPrep DNA Library Preparation Module for MGI (MGI, CHN). The libraries were sequenced on the MGISEQ-T7 platform with 100 bp paired-end reads.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-13\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ERNA-Seq raw data quality control, gene expression analysis, and immune cell \u003Cstrong\u003Eabundance estimation\u003C\/strong\u003E\u003C\/h3\u003E\u003Cp id=\u0022p-32\u0022\u003ERaw sequencing data (raw reads) from MGISEQ-T7 was processed to filter out low-quality reads. Clean reads from each sample were aligned against the hg19 reference by STAR (v2.7.8) (\u003Ca id=\u0022xref-ref-26-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26\u003C\/a\u003E). The read counts and transcripts per million (TPM) values were calculated based on aligned RNA sequencing reads to reference transcripts downloaded from gencode (v27lift37) database, as implemented in rsem (v1.3.0) (\u003Ca id=\u0022xref-ref-27-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-27\u0022\u003E27\u003C\/a\u003E). Based on the gene expression matrix, R packages xCell (\u003Ca id=\u0022xref-ref-28-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-28\u0022\u003E28\u003C\/a\u003E) and web tool ImmunCellAI (\u003Ca id=\u0022xref-ref-29-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-29\u0022\u003E29\u003C\/a\u003E) were used to estimate the infiltration abundance of immune cells for each sample.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-14\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ET cell receptor sequencing and analysis\u003C\/h3\u003E\u003Cp id=\u0022p-33\u0022\u003EFor T cell receptor (TCR) sequencing, total RNA was isolated from peripheral blood mononuclear cells (PBMCs) by RNeasy Plus Mini Kit (Qiagen, USA) according to the manufacturer\u2019s instructions. Qubit\u2122 RNA HS Assay Kit (ThermoFisher Scientific, USA) was applied to determine the final concentration. Then TCR \u03b2-chain of CDR3 was amplified by Multi-IR Library Prep Kit (iGeneTech, CHN). Sequencing procedures were utilized by the MGISEQ-T7 platform with 100-bp paired-end reads. Fastq reads were trimmed based on their low-quality 3\u2019 ends to base. Trimmed pair-end reads were integrated according to overlapping alignment with the modified Needleman-Wunsch algorithm. MiXCR (v2.1.10) (\u003Ca id=\u0022xref-ref-30-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-30\u0022\u003E30\u003C\/a\u003E) was performed to identify the CDR3 sequences of V-D-J gene segments with reference sequences from the IMGT (\u003Ca id=\u0022xref-ref-31-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-31\u0022\u003E31\u003C\/a\u003E). VDJtools (v1.2.1) (\u003Ca id=\u0022xref-ref-32-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-32\u0022\u003E32\u003C\/a\u003E) was utilized to assess the immune repertoire sequencing. A frequency-based correction was performed on samples. The diversity of the TCR repertoire was calculated with the Shannon-Wiener index formula represents the frequency of clonotype i for the sample with n unique clonotypes. The evenness of the TCR repertoire was calculated with the formula , where H was Shannon Weiner index and S was the total number of species in a sample, across all samples in the dataset. Clonality is defined as a normalized Shannon index over n unique clones: clonality = 1 \u2212 H\/ln(n). The D50 index was also performed to evaluate the diversity according to the top 50% of the total TCR clones in the samples. According to clonotype abundance, TCR clonotypes were defined as large clones when their frequency \u0026gt; 0.001. Based on the frequency ranking, the top 20 most frequent TCR clones and large clones are defined as the predominant TCR clones.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-15\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStatistical analysis\u003C\/h3\u003E\u003Cp id=\u0022p-34\u0022\u003EAll statistical analyses were implemented by R 4.0 software or SPSS 27.0. Medians and inter quartile range (IQRs) were provided for distributions of observation duration and time intervals. Wilcoxon\u2019s Rank-Sum test was used to compare across independent groups. Wilcoxon\u2019s Signed-Rank test was used for the pairwise comparison samples. All reported \u003Cem\u003EP\u003C\/em\u003E values are two-sided, and \u003Cem\u003EP\u003C\/em\u003E values less than 0.05 were considered statistically significant.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-16\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EResults\u003C\/h2\u003E\u003Cdiv id=\u0022sec-17\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EOverview of the patient cohort\u003C\/h3\u003E\u003Cp id=\u0022p-35\u0022\u003EFrom May 2020 to November 2023, 50 patients diagnosed with NSCLC at stage IIA-IIIA were screened for eligibility, of which 38 received two cycles of modified neoadjuvant chemo-immunotherapy (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFig. 1A\u003C\/a\u003E\u003C\/strong\u003E). Each cycle featured two phases, corresponding to chemotherapy and immunotherapy (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-1-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFig. 1B\u003C\/a\u003E\u003C\/strong\u003E). Following modified neoadjuvant chemo-immunotherapy, 31 patients underwent R0 resection (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-1-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1A\u003C\/a\u003E and Table S1\u003C\/strong\u003E). The postoperative tissues were subjected to pathological evaluation. Samples from a representative patient (P2) who achieved pCR after neoadjuvant treatment exhibited morphological alterations, characterized by extracellular mucin pools and fibrosis (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-1-4\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFig. 1C\u003C\/a\u003E\u003C\/strong\u003E). Computed tomography scans demonstrated the obliteration of lung lesions following neoadjuvant therapy (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-1-5\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFig. 1D\u003C\/a\u003E\u003C\/strong\u003E). 74.2% (27\/31) participants received the modified adjuvant chemo-immunotherapy (from time-point c3d0 to c4d21) (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-1-6\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFig. 1A and B\u003C\/a\u003E\u003C\/strong\u003E; \u003Cstrong\u003ETable S1\u003C\/strong\u003E). Detailed treatment regimens are provided in \u003Cstrong\u003ETable S2\u003C\/strong\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Overview of study design and representative images. (A) Flow diagram of the study. (B) Trial schema of the study. Patients with NSCLC received modified neoadjuvant chemo-immunotherapy, followed by surgical resection and modified adjuvant chemo-immunotherapy. Tumor tissues were collected at baseline and the surgery phase. Serial blood samples were collected at baseline and each time-point for TCR and ctDNA sequencing. (C) Representative hematoxylin and eosin staining of tumor specimens obtained from patient 2 (P2), who obtained pCR. (D) Representative computed tomographic imaging of lung lesions of P2. NSCLC, non-small cell lung cancer; TCR, T-cell receptor; ctDNA, circulating tumor DNA; pCR, pathologic complete response.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-721721426\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;\u0026lt;span class=\u0026quot;caption-title\u0026quot;\u0026gt;Overview of study design and representative images.\u0026lt;\/span\u0026gt; \u0026lt;strong\u0026gt;(A)\u0026lt;\/strong\u0026gt; Flow diagram of the study. \u0026lt;strong\u0026gt;(B)\u0026lt;\/strong\u0026gt; Trial schema of the study. Patients with NSCLC received modified neoadjuvant chemo-immunotherapy, followed by surgical resection and modified adjuvant chemo-immunotherapy. Tumor tissues were collected at baseline and the surgery phase. Serial blood samples were collected at baseline and each time-point for TCR and ctDNA sequencing. \u0026lt;strong\u0026gt;(C)\u0026lt;\/strong\u0026gt; Representative hematoxylin and eosin staining of tumor specimens obtained from patient 2 (P2), who obtained pCR. \u0026lt;strong\u0026gt;(D)\u0026lt;\/strong\u0026gt; Representative computed tomographic imaging of lung lesions of P2. NSCLC, non-small cell lung cancer; TCR, T-cell receptor; ctDNA, circulating tumor DNA; pCR, pathologic complete response.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Fig. 1\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022385\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Fig. 1\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022385\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Fig. 1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFig. 1\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EOverview of study design and representative images.\u003C\/span\u003E\u003Cp id=\u0022p-36\u0022 class=\u0022first-child\u0022\u003E\u003Cstrong\u003E(A)\u003C\/strong\u003E Flow diagram of the study. \u003Cstrong\u003E(B)\u003C\/strong\u003E Trial schema of the study. Patients with NSCLC received modified neoadjuvant chemo-immunotherapy, followed by surgical resection and modified adjuvant chemo-immunotherapy. Tumor tissues were collected at baseline and the surgery phase. Serial blood samples were collected at baseline and each time-point for TCR and ctDNA sequencing. \u003Cstrong\u003E(C)\u003C\/strong\u003E Representative hematoxylin and eosin staining of tumor specimens obtained from patient 2 (P2), who obtained pCR. \u003Cstrong\u003E(D)\u003C\/strong\u003E Representative computed tomographic imaging of lung lesions of P2. NSCLC, non-small cell lung cancer; TCR, T-cell receptor; ctDNA, circulating tumor DNA; pCR, pathologic complete response.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-37\u0022\u003EMost patients were men (78.7%) and had a smoking history (81.6%). The median age of patients was 64 years (range: 37-77). All patients had ECOG performance status of 0 or 1. Baseline patient characteristics are summarized in \u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E\u003C\/strong\u003E and detailed in \u003Cstrong\u003ETable S1\u003C\/strong\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/978337\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/978337\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/978337\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1\u003C\/span\u003E \u003Cp id=\u0022p-38\u0022 class=\u0022first-child\u0022\u003EBaseline clinical characteristics of patients.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-18\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EClinical efficacy and safety\u003C\/h3\u003E\u003Cp id=\u0022p-39\u0022\u003EAfter neoadjuvant therapy, 39.5% (15\/38) patients achieved radiological downstaging (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFig. 2A\u003C\/a\u003E\u003C\/strong\u003E; \u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E\u003C\/strong\u003E). The ratio of patients with CR, PR, and stable disease (SD) was 5.3% (2\/38), 68.4% (26\/38), and 26.3% (10\/38), respectively, yielding an ORR of 73.7% (28\/38) (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-2-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFig. 2B\u003C\/a\u003E\u003C\/strong\u003E). 91.3% (21 of 23) were recurrence-free (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-2-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFig. 2C\u003C\/a\u003E\u003C\/strong\u003E). The median interval between the last dose of sintilimab and surgery was 33 days (interquartile ranges (IQRs) 5.55 days) (\u003Cstrong\u003ETable S1\u003C\/strong\u003E). 58.1% (18\/31) patients achieved a MPR, including 12 patients with a pCR, and 41.9% (13\/31) patients achieved a non-MPR (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-2-4\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFig. 2D\u003C\/a\u003E\u003C\/strong\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Clinical efficacy of modified neoadjuvant chemo-immunotherapy. (A) Tumor size changes from baseline based on radiological imaging. (B) Ring diagram showed the rate of overall response according to RECIST criteria (CR, PR, and SD) in patients. (C) Swimmer plot of 31 patients who underwent R0 resection involved in this trial. (D) Barplot showed the number of patients distributed in pathological response (pCR in blue, MPR in green, and non-MPR in red, respectively). (E) DFS curve for patients with modified treatment. CR, complete response; PR, partial response; SD, stable disease; pCR, completed pathological response; MPR, major pathological response; DFS, disease free survival.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-721721426\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;\u0026lt;span class=\u0026quot;caption-title\u0026quot;\u0026gt;Clinical efficacy of modified neoadjuvant chemo-immunotherapy.\u0026lt;\/span\u0026gt; \u0026lt;strong\u0026gt;(A)\u0026lt;\/strong\u0026gt; Tumor size changes from baseline based on radiological imaging. \u0026lt;strong\u0026gt;(B)\u0026lt;\/strong\u0026gt; Ring diagram showed the rate of overall response according to RECIST criteria (CR, PR, and SD) in patients. \u0026lt;strong\u0026gt;(C)\u0026lt;\/strong\u0026gt; Swimmer plot of 31 patients who underwent R0 resection involved in this trial. \u0026lt;strong\u0026gt;(D)\u0026lt;\/strong\u0026gt; Barplot showed the number of patients distributed in pathological response (pCR in blue, MPR in green, and non-MPR in red, respectively). \u0026lt;strong\u0026gt;(E)\u0026lt;\/strong\u0026gt; DFS curve for patients with modified treatment. CR, complete response; PR, partial response; SD, stable disease; pCR, completed pathological response; MPR, major pathological response; DFS, disease free survival.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Fig. 2\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F2.medium.gif\u0022 width=\u0022385\u0022 height=\u0022440\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Fig. 2\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F2.medium.gif\u0022 width=\u0022385\u0022 height=\u0022440\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Fig. 2\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFig. 2\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EClinical efficacy of modified neoadjuvant chemo-immunotherapy.\u003C\/span\u003E\u003Cp id=\u0022p-40\u0022 class=\u0022first-child\u0022\u003E\u003Cstrong\u003E(A)\u003C\/strong\u003E Tumor size changes from baseline based on radiological imaging. \u003Cstrong\u003E(B)\u003C\/strong\u003E Ring diagram showed the rate of overall response according to RECIST criteria (CR, PR, and SD) in patients. \u003Cstrong\u003E(C)\u003C\/strong\u003E Swimmer plot of 31 patients who underwent R0 resection involved in this trial. \u003Cstrong\u003E(D)\u003C\/strong\u003E Barplot showed the number of patients distributed in pathological response (pCR in blue, MPR in green, and non-MPR in red, respectively). \u003Cstrong\u003E(E)\u003C\/strong\u003E DFS curve for patients with modified treatment. CR, complete response; PR, partial response; SD, stable disease; pCR, completed pathological response; MPR, major pathological response; DFS, disease free survival.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/978332\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/978332\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2\u003C\/span\u003E \u003Cp id=\u0022p-41\u0022 class=\u0022first-child\u0022\u003EResponse to modified neoadjuvant chemo-immunotherapy\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-42\u0022\u003EFor patients receiving adjuvant therapy, the median interval between the surgery and the adjuvant therapy was 32.1 days (IQRs 7.2 days) (\u003Cstrong\u003ETable S1\u003C\/strong\u003E). Up to January 18, 2024, the median follow-up was 14.37 months (IQRs 24.22 months) (\u003Cstrong\u003ETable S1\u003C\/strong\u003E). The median OS are not reached (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-2-5\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFig. 2E\u003C\/a\u003E\u003C\/strong\u003E). 44.7% (17\/38) patients experienced at least one TRAE (\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-3-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E\u003C\/strong\u003E). Grade 3 TRAEs occurred only in one patient. The most common grade 1 or 2 TRAEs were nausea (15.8%). Previously unreported toxic effects were not observed, and there were no instances of discontinuation of modified neoadjuvant chemo-immunotherapy due to toxicity.\u003C\/p\u003E\u003Cdiv id=\u0022T3\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/978336\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/978336\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/978336\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 3\u003C\/span\u003E \u003Cp id=\u0022p-43\u0022 class=\u0022first-child\u0022\u003ESummary of treatment-related adverse events\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-19\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ELow-dose chemotherapy combined with delayed immunotherapy has a positive effect on T lymphocytes\u003C\/h3\u003E\u003Cp id=\u0022p-44\u0022\u003ETo investigate whether dynamic changes in peripheral blood TCR repertoire were associated with treatment efficiency during modified chemo-immunotherapy, 49 peripheral blood samples were collected from serial time-points and evaluated using TCR sequencing (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-3-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003EFig. 3A\u003C\/a\u003E\u003C\/strong\u003E). Since the predominant number of TCR clones is an important indicator of immune response and treatment efficacy (\u003Ca id=\u0022xref-ref-15-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-33-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-33\u0022\u003E33\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-35-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-35\u0022\u003E35\u003C\/a\u003E), the frequency of the top 20 TCR clones was analyzed at each treatment phase. Significant increase of top 20 TCR clones were observed in phase 1 to 3 (all \u003Cem\u003EP\u003C\/em\u003E \u0026lt; 0.0001; \u003Cstrong\u003E\u003Ca id=\u0022xref-fig-3-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003EFig. 3B\u003C\/a\u003E\u003C\/strong\u003E; \u003Cstrong\u003EFig. S1\u003C\/strong\u003E). An overall increase of top 20 frequency was observed in the first cycle of neoadjuvant therapy (C1). In contrast, no significant changes were observed during adjuvant therapy (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-3-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003EFig. 3C\u003C\/a\u003E\u003C\/strong\u003E; \u003Cstrong\u003ETable S3\u003C\/strong\u003E). These results suggested that the peripheral blood-derived top 20 TCR clones were phased increased not only during low-dose chemotherapy, but also during immunotherapy within neoadjuvant therapy.\u003C\/p\u003E\u003Cdiv id=\u0022F3\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F3.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Dynamic changes in T cell repertoire during therapy. (A) The schematic of samples collection and analyses performed for each patient. Top boxes represent therapeutic phases, blue for chemotherapy, yellow for immunotherapy, and purple for operation. TCR sequencing is indicated as circle. Square and triangle represents ctDNA and RNA sequencing, respectively. Solid shapes are defined as available data, while open shapes are defined as unavailable data. (B) Comparison of top 20 TCR clones at different therapeutic phases. (C) Comparison of top 20 TCR clones at different therapeutic cycles. For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents the median; the upper whisker is the min[max(x), Q3 + 1.5 \u0026#xD7; IQR], and the lower whisker is the max[min(x), Q1 - 1.5 \u0026#xD7; IQR], where x represents the data, Q3 is the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. (D) Comparison of large TCR clones at different therapeutic phases. (E) Comparison of large TCR clones at different therapeutic cycles. Average and SD are shown. Wilcoxon\u0026#x2019;s Signed-Rank test was used for comparison in B-E (*p \u0026lt; 0.05, **p \u0026lt; 0.01, ***p \u0026lt; 0.001, **** p \u0026lt; 0.0001). (F) Changes in diversity (Shannon index) of TCR clones for each patient. TCR, T-cell receptor; ctDNA, circulating tumor DNA; IQR, interquartile range.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-721721426\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;\u0026lt;span class=\u0026quot;caption-title\u0026quot;\u0026gt;Dynamic changes in T cell repertoire during therapy.\u0026lt;\/span\u0026gt; \u0026lt;strong\u0026gt;(A)\u0026lt;\/strong\u0026gt; The schematic of samples collection and analyses performed for each patient. Top boxes represent therapeutic phases, blue for chemotherapy, yellow for immunotherapy, and purple for operation. TCR sequencing is indicated as circle. Square and triangle represents ctDNA and RNA sequencing, respectively. Solid shapes are defined as available data, while open shapes are defined as unavailable data. \u0026lt;strong\u0026gt;(B)\u0026lt;\/strong\u0026gt; Comparison of top 20 TCR clones at different therapeutic phases. \u0026lt;strong\u0026gt;(C)\u0026lt;\/strong\u0026gt; Comparison of top 20 TCR clones at different therapeutic cycles. For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents the median; the upper whisker is the min[max(x), Q3 + 1.5 \u0026#xD7; IQR], and the lower whisker is the max[min(x), Q1 - 1.5 \u0026#xD7; IQR], where x represents the data, Q3 is the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. \u0026lt;strong\u0026gt;(D)\u0026lt;\/strong\u0026gt; Comparison of large TCR clones at different therapeutic phases. \u0026lt;strong\u0026gt;(E)\u0026lt;\/strong\u0026gt; Comparison of large TCR clones at different therapeutic cycles. Average and SD are shown. Wilcoxon\u0026#x2019;s Signed-Rank test was used for comparison in B-E (*\u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt; \u0026lt; 0.05, **\u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt; \u0026lt; 0.01, ***\u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt; \u0026lt; 0.001, **** \u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt; \u0026lt; 0.0001). \u0026lt;strong\u0026gt;(F)\u0026lt;\/strong\u0026gt; Changes in diversity (Shannon index) of TCR clones for each patient. TCR, T-cell receptor; ctDNA, circulating tumor DNA; IQR, interquartile range.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Fig. 3\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F3.medium.gif\u0022 width=\u0022356\u0022 height=\u0022440\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Fig. 3\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F3.medium.gif\u0022 width=\u0022356\u0022 height=\u0022440\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F3.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Fig. 3\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F3.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFig. 3\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EDynamic changes in T cell repertoire during therapy.\u003C\/span\u003E\u003Cp id=\u0022p-45\u0022 class=\u0022first-child\u0022\u003E\u003Cstrong\u003E(A)\u003C\/strong\u003E The schematic of samples collection and analyses performed for each patient. Top boxes represent therapeutic phases, blue for chemotherapy, yellow for immunotherapy, and purple for operation. TCR sequencing is indicated as circle. Square and triangle represents ctDNA and RNA sequencing, respectively. Solid shapes are defined as available data, while open shapes are defined as unavailable data. \u003Cstrong\u003E(B)\u003C\/strong\u003E Comparison of top 20 TCR clones at different therapeutic phases. \u003Cstrong\u003E(C)\u003C\/strong\u003E Comparison of top 20 TCR clones at different therapeutic cycles. For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents the median; the upper whisker is the min[max(x), Q3 + 1.5 \u00d7 IQR], and the lower whisker is the max[min(x), Q1 - 1.5 \u00d7 IQR], where x represents the data, Q3 is the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. \u003Cstrong\u003E(D)\u003C\/strong\u003E Comparison of large TCR clones at different therapeutic phases. \u003Cstrong\u003E(E)\u003C\/strong\u003E Comparison of large TCR clones at different therapeutic cycles. Average and SD are shown. Wilcoxon\u2019s Signed-Rank test was used for comparison in B-E (*\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.05, **\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.01, ***\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.001, **** \u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.0001). \u003Cstrong\u003E(F)\u003C\/strong\u003E Changes in diversity (Shannon index) of TCR clones for each patient. TCR, T-cell receptor; ctDNA, circulating tumor DNA; IQR, interquartile range.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-46\u0022\u003EAccording to clonotype abundance, the TCR clones were divided into 3 clonotypes, including large (frequency \u0026gt; 0.001), median (0.001-0.0001), and small (\u0026lt; 0.0001) clones. A markedly increase of large clones was observed during neoadjuvant therapy (all \u003Cem\u003EP\u003C\/em\u003E \u0026lt; 0.05) (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-3-4\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003EFig. 3D\u003C\/a\u003E and \u003Ca id=\u0022xref-fig-3-5\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003EE\u003C\/a\u003E\u003C\/strong\u003E), consistent with the trend of top 20 TCR clones. No significant difference was observed in the diversity, evenness, and clonality of TCR clones across the whole treatment procedure (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-3-6\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003EFig. 3F\u003C\/a\u003E\u003C\/strong\u003E; \u003Cstrong\u003EFig. S2; Table S4\u003C\/strong\u003E). The changes of T lymphocytes in the tumor microenvironment across the neoadjuvant therapy were analyzed based on transcriptomic data. As shown in \u003Cstrong\u003EFigure S3\u003C\/strong\u003E, the CD4+ and CD8+ T lymphocytes tended to increase during neoadjuvant therapy. Collectively, the neoadjuvant treatment had a positive effect on T lymphocytes.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-20\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EReduced tumor burden in ctDNA was observed during neoadjuvant therapy\u003C\/h3\u003E\u003Cp id=\u0022p-47\u0022\u003ETo monitor the dynamic changes of tumor burden in ctDNA during therapy, peripheral blood samples were collected at serial time-points (T0 to T7) and evaluated via ctDNA sequencing. The landscape of genomic alternations was shown in \u003Ca id=\u0022xref-fig-4-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F4\u0022\u003EFigure 4A\u003C\/a\u003E. Among the detected genes, \u003Cem\u003ETP53\u003C\/em\u003E (50%) was the most frequently mutated gene, followed by \u003Cem\u003EARID1A\u003C\/em\u003E (11%), \u003Cem\u003EDNMT3A\u003C\/em\u003E (11%), and \u003Cem\u003EPIK3CA\u003C\/em\u003E (11%) (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-4-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F4\u0022\u003EFig. 4A\u003C\/a\u003E\u003C\/strong\u003E; \u003Cstrong\u003ETable S5\u003C\/strong\u003E). Throughout the entire treatment, the maximal somatic variant allelic frequency (maxVAF) of ctDNA had a declining trend, especially in PH1 (T0 to T1) with dramatically decreased (\u003Cem\u003EP\u003C\/em\u003E \u0026lt; 0.05) (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-4-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F4\u0022\u003EFig. 4B\u003C\/a\u003E\u003C\/strong\u003E; \u003Cstrong\u003EFig. S4\u003C\/strong\u003E), indicating that low-dose chemotherapy would induce tumor cell death thus reducing tumor burden. Notably, we observed that the changes in TCR and ctDNA exhibited opposite trends during the neoadjuvant therapy (\u003Cstrong\u003E\u003Ca id=\u0022xref-fig-3-7\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003EFig.3B\u003C\/a\u003E and \u003Ca id=\u0022xref-fig-3-8\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003E3D\u003C\/a\u003E; \u003Ca id=\u0022xref-fig-4-4\u0022 class=\u0022xref-fig\u0022 href=\u0022#F4\u0022\u003EFig. 4B\u003C\/a\u003E\u003C\/strong\u003E). Taken together, these results suggest that low-dose chemotherapy combined with delayed immunotherapy not only cause the increase of tumor antigens shed into blood but also stimulate the body\u2019s immunity to produce more tumor antigen-specific T lymphocytes.\u003C\/p\u003E\u003Cdiv id=\u0022F4\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F4.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Characterization of ctDNA and the alteration of tumor burden during treatment. (A) Genomic landscape of mutations detected in plasma via ctDNA sequencing. Frequency of mutated genes were shown on the bar of middle and the proportion was shown in numerical form. Counts of mutations for each sample were displayed on top bar. Frequency for each of the six substitutions of the bases spectrum was shown on right. The scale lines below show the proportion of various mutation substitutions. (B) Changes in maxVAF across the entire course of therapy. Wilcoxon\u0026#x2019;s Signed-Rank test was used for comparison. (*p \u0026lt; 0.05). ctDNA, circulating tumor DNA; maxVAF, maximal somatic variant allelic frequency.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-721721426\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;\u0026lt;span class=\u0026quot;caption-title\u0026quot;\u0026gt;Characterization of ctDNA and the alteration of tumor burden during treatment.\u0026lt;\/span\u0026gt; \u0026lt;strong\u0026gt;(A)\u0026lt;\/strong\u0026gt; Genomic landscape of mutations detected in plasma via ctDNA sequencing. Frequency of mutated genes were shown on the bar of middle and the proportion was shown in numerical form. Counts of mutations for each sample were displayed on top bar. Frequency for each of the six substitutions of the bases spectrum was shown on right. The scale lines below show the proportion of various mutation substitutions. \u0026lt;strong\u0026gt;(B)\u0026lt;\/strong\u0026gt; Changes in maxVAF across the entire course of therapy. Wilcoxon\u0026#x2019;s Signed-Rank test was used for comparison. (*\u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt; \u0026lt; 0.05). ctDNA, circulating tumor DNA; maxVAF, maximal somatic variant allelic frequency.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Fig. 4\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F4.medium.gif\u0022 width=\u0022440\u0022 height=\u0022408\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Fig. 4\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F4.medium.gif\u0022 width=\u0022440\u0022 height=\u0022408\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F4.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Fig. 4\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/04\/15\/2024.07.11.24310105\/F4.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFig. 4\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003ECharacterization of ctDNA and the alteration of tumor burden during treatment.\u003C\/span\u003E\u003Cp id=\u0022p-48\u0022 class=\u0022first-child\u0022\u003E\u003Cstrong\u003E(A)\u003C\/strong\u003E Genomic landscape of mutations detected in plasma via ctDNA sequencing. Frequency of mutated genes were shown on the bar of middle and the proportion was shown in numerical form. Counts of mutations for each sample were displayed on top bar. Frequency for each of the six substitutions of the bases spectrum was shown on right. The scale lines below show the proportion of various mutation substitutions. \u003Cstrong\u003E(B)\u003C\/strong\u003E Changes in maxVAF across the entire course of therapy. Wilcoxon\u2019s Signed-Rank test was used for comparison. (*\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.05). ctDNA, circulating tumor DNA; maxVAF, maximal somatic variant allelic frequency.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-21\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EDiscussion\u003C\/h2\u003E\u003Cp id=\u0022p-49\u0022\u003EIn recent clinical trials, the combination of neoadjuvant chemotherapy with immunotherapy by administering them concurrently in patients with resectable NSCLC has brought about longer event-free survival (\u003Ca id=\u0022xref-ref-6-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-8-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-36-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-36\u0022\u003E36\u003C\/a\u003E). Although chemotherapy promotes tumor cell death and T lymphocyte infiltration (\u003Ca id=\u0022xref-ref-17-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-18-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E), it may also have negative effects on T lymphocyte proliferation (\u003Ca id=\u0022xref-ref-37-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-37\u0022\u003E37\u003C\/a\u003E). Therefore, in the context of combination therapy, the dosage of chemotherapy and the timing of its administration relative to the other treatment need to be better adjusted to optimize the current therapeutic efficacy.\u003C\/p\u003E\u003Cp id=\u0022p-50\u0022\u003EOur previous findings from both in vitro experiments and clinical trials have suggested that administering PD-1\/PD-L1 inhibitors at 1-10 days (especially 3-5 days) after chemotherapy in lung cancer patients may be more effective than administering them before or concurrently (\u003Ca id=\u0022xref-ref-14-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E). In this trial, we reported the safety and efficacy of low-dose platinum-based chemotherapy combined with delayed immunotherapy for patients with stage IIA to IIIA resectable NSCLC. After modified neoadjuvant therapy, ORR was achieved in 73.7% (28\/38) of patients, which was higher than the report of CheckMate-816 (54%) (\u003Ca id=\u0022xref-ref-6-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E) and comparable to those of NADIM (76%) (\u003Ca id=\u0022xref-ref-8-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E) and LungMate 002 (76%) (\u003Ca id=\u0022xref-ref-38-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-38\u0022\u003E38\u003C\/a\u003E) trials. MPR was achieved in 47.4% (18\/38) patients, with 31.6% (12\/38) achieving pCR. During a median follow-up of 14.37 months, 91.3% (21\/23) patients were recurrence-free. These results indicated that modified neoadjuvant chemo-immunotherapy was effective in patients with resectable NSCLC. Only 2.6% (1\/38) patients experienced serious TRAEs after receiving modified neoadjuvant treatment, which is lower than the rates reported in CheckMate 816 (33.5%), NAMID (30.0%) (\u003Ca id=\u0022xref-ref-8-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E), and LungMate 002 (6.0%) (\u003Ca id=\u0022xref-ref-38-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-38\u0022\u003E38\u003C\/a\u003E) trials. The reduction of chemotherapeutics may contribute to the low incidence of serious TRAEs. Additionally, we did not observe treatment discontinuation due to toxicity. These results provide evidences that low-dose platinum-based chemotherapy combined with delayed immunotherapy as a neoadjuvant therapy is safe and less toxic.\u003C\/p\u003E\u003Cp id=\u0022p-51\u0022\u003EPrevious research has illustrated an association between clinical benefit and TCR repertoire as well as ctDNA level at baseline (\u003Ca id=\u0022xref-ref-39-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-39\u0022\u003E39\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-40-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-40\u0022\u003E40\u003C\/a\u003E). However, the dynamic changes in the TCR repertoire and ctDNA level during neoadjuvant treatment have been less studied. In our study, we found that the predominant TCR clones were greatly increased after the treatment of chemotherapy from phase 1 to 3, indicating that low-dose platinum-based chemotherapy did not inhibit the proliferation of predominant T cell clones which create a beneficial microenvironment for subsequent immunotherapy. Moreover, ICI treatment significantly increased the number of predominant TCR clones during neoadjuvant therapy, suggesting that immunotherapy has a positive impact on TCR clones, consistent with the study by Forde et al (\u003Ca id=\u0022xref-ref-41-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-41\u0022\u003E41\u003C\/a\u003E). During adjuvant therapy, no significant fluctuation in the predominant TCR clones was observed, probably because the tumor lesions were cleared. Under such circumstances, no tumor antigen was released, thus no tumor antigen-specific T cells were proliferated. Similarly, no significant change was observed in evenness or clonality of TCR. MaxVAF of ctDNA was dramatically dropped during phase 1, which is accordance with previous studies (\u003Ca id=\u0022xref-ref-42-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-42\u0022\u003E42\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-44-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-44\u0022\u003E44\u003C\/a\u003E). Notably, the maxVAF of ctDNA and predominant TCR clones showed opposite trends of change in phase 1. Moreover, the maxVAF of ctDNA was close to 0 during adjuvant therapy stage.\u003C\/p\u003E\u003Cp id=\u0022p-52\u0022\u003EOur study had several limitations that need to be acknowledged. First, it was a pilot study with a relatively small cohort and lacked a control arm. Therefore, validation of our findings in larger cohorts is necessary. Second, the follow-up period was short, and longer-term results are needed to investigate whether modified therapy provides long-term survival benefits. Finally, innovative techniques should be incorporated to further explore the underlying mechanisms of superior clinical efficacy and reduced TRAEs.\u003C\/p\u003E\u003Cp id=\u0022p-53\u0022\u003EIn this study, the modified neoadjuvant low-dose platinum-based chemotherapy combined with delayed immunotherapy in patients with resectable NSCLC exhibited promising efficacy and feasibility. The multi-omics analyses provide the dynamic trajectories of the TCR repertoire and tumor burden, which can aim in better understanding the mechanisms of superior efficiency and the feasibility of modified chemo-immunotherapy. In the future, it is possible to conduct large-scale clinical research using this modified chemo-immunotherapy.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-23\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAuthor\u2019s contributions\u003C\/h2\u003E\u003Cp id=\u0022p-55\u0022\u003EC.Y. Liang: Conceptualization, Formal analysis, Methodology, Writing - original draft. Q. Song: Formal analysis, Methodology, Funding acquisition, Writing - original draft. W.H. Zhou and N. Li: Formal analysis, Methodology, Writing - original draft. C.H. Pan, Q. Xiong B. Yang, and X.L Zhang: Formal analysis. S.H Zhao, W.W. Shi, X. Yan, J.T. Guo, S.J. Sun, Z.H. Dong, and Y.P. Long: Validation, Writing - reviewing \u0026amp; editing. B. Yang, J. Li, Y. Hu, and H.T. Luo: Conceptualization, Investigation, Validation, Verification of underlying data, Supervision, Writing - reviewing \u0026amp; editing.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-24\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EFunding\u003C\/h2\u003E\u003Cp id=\u0022p-56\u0022\u003EThis study was supported by the National Natural Science Fund of the People\u2019s Republic of China (NSFC) No.81902912.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-25\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData availability statement\u003C\/h2\u003E\u003Cp id=\u0022p-57\u0022\u003EAll the analysis data can be found in the supplementary tables. The dataset supporting the conclusions of this article is available in the Genome Sequence Archive for Human (GSA-H) repository with accession number (HRA002904) and can be accessed thru the URL (BIG Search - National Genomics Data Center - BIG Search (cncb.ac.cn)) after reasonable request.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-26\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EDeclarations\u003C\/h2\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-27\u0022\u003E\u003Ch3\u003EEthics approval and consent to participate\u003C\/h3\u003E\u003Cp id=\u0022p-58\u0022\u003EThis study was conducted according to the guidelines of the Ethics Committee of the General Hospital of the People\u2019s Liberation Army (S2020-144-01) and written informed consent was obtained from all participants.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-28\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EConsent for publication\u003C\/h2\u003E\u003Cp id=\u0022p-59\u0022\u003ENot applicable.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-29\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ECompeting interests\u003C\/h2\u003E\u003Cp id=\u0022p-60\u0022\u003EThe authors declare no conflicts of interest.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-30\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EFunding\u003C\/h2\u003E\u003Cp id=\u0022p-61\u0022\u003EThis study was funded by the National Natural Science Fund of the People\u2019s Republic of China (NSFC; No.81902912).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-31\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ESupplementary materials\u003C\/h2\u003E\u003Cp id=\u0022p-62\u0022\u003E\u003Cstrong\u003EFig. S1 Dynamic change of top 20 TCR clones in the distinct phases.\u003C\/strong\u003E\u003C\/p\u003E\u003Cp id=\u0022p-63\u0022\u003E\u003Cstrong\u003E(A)\u003C\/strong\u003E Changes of top 20 TCR clones of P1, P2, P3, P10, P11, and P12 in T0 to T1 (PH 1). \u003Cstrong\u003E(B)\u003C\/strong\u003E Changes of top 20 TCR clones of P1, P2, P5, P10, P11, and P12 in T1 to T2 (PH 2). \u003Cstrong\u003E(C)\u003C\/strong\u003E Changes of top 20 TCR clones of P2, P4, P10, P11, and P12 in T2 to T3 (PH 3). For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents the median; the upper whisker is the min[max(x), Q3 + 1.5 \u00d7 IQR], and the lower whisker is the max[min(x), Q1 - 1.5 \u00d7 IQR], where x represents the data, Q3 is the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. Wilcoxon\u2019s Signed-Rank test was used for comparison (*\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.05, **\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.01, ***\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.001, **** \u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.0001). TCR, T-cell receptor; IQR, interquartile range.\u003C\/p\u003E\u003Cp id=\u0022p-64\u0022\u003E\u003Cstrong\u003EFig. S2 Characterization of temporal dynamics of the T cell repertoire in the longitudinal blood.\u003C\/strong\u003E\u003C\/p\u003E\u003Cp id=\u0022p-65\u0022\u003E\u003Cstrong\u003E(A)\u003C\/strong\u003E Changes of the D50 index among patients. \u003Cstrong\u003E(B)\u003C\/strong\u003E Changes of Pielou index (evenness) among patients. \u003Cstrong\u003E(C)\u003C\/strong\u003E Changes of clonality index among patients.\u003C\/p\u003E\u003Cp id=\u0022p-66\u0022\u003E\u003Cstrong\u003EFig. S3 Infiltration of CD4+ and CD8+ T lymphocytes after modified neoadjuvant therapy.\u003C\/strong\u003E\u003C\/p\u003E\u003Cp id=\u0022p-67\u0022\u003E\u003Cstrong\u003E(A)\u003C\/strong\u003E Relative proportion of lymphocytes was assessed by ImmunCellAI. \u003Cstrong\u003E(B)\u003C\/strong\u003E Relative proportion of lymphocytes was assessed by xCell. For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents the median; the upper whisker is the min[max(x), Q3 + 1.5 \u00d7 IQR], and the lower whisker is the max[min(x), Q1 - 1.5 \u00d7 IQR], where x represents the data, Q3 is the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. Wilcoxon\u2019s Signed-Rank test was used for comparison. Tcm, central memory T cells; Tem, Effector memory T cells; IQR, interquartile range.\u003C\/p\u003E\u003Cp id=\u0022p-68\u0022\u003E\u003Cstrong\u003EFig. S4 Change in maxVAF across different phases.\u003C\/strong\u003E For boxplots, each box indicates the first quartile (Q1) and third quartile (Q3), and the black horizontal line represents the median; the upper whisker is the min[max(x), Q3 + 1.5 \u00d7 IQR], and the lower whisker is the max[min(x), Q1 - 1.5 \u00d7 IQR], where x represents the data, Q3 is the 75th percentile, Q1 is the 25th percentile, and IQR = Q3 - Q1. Wilcoxon\u2019s Signed-Rank test was used for comparison. IQR, interquartile range.\u003C\/p\u003E\u003Cp id=\u0022p-69\u0022\u003E\u003Cstrong\u003ETable S1. Clinical characteristics of patients\u003C\/strong\u003E\u003C\/p\u003E\u003Cp id=\u0022p-70\u0022\u003E\u003Cstrong\u003ETable S2. List of treatment regimens\u003C\/strong\u003E\u003C\/p\u003E\u003Cp id=\u0022p-71\u0022\u003E\u003Cstrong\u003ETable S3. List of top 20 TCR clones frequency across the whole modified therapy\u003C\/strong\u003E\u003C\/p\u003E\u003Cp id=\u0022p-72\u0022\u003E\u003Cstrong\u003ETable S4. TCR characteristics across the whole modified therapy\u003C\/strong\u003E\u003C\/p\u003E\u003Cp id=\u0022p-73\u0022\u003E\u003Cstrong\u003ETable S5. T cells abundance estimated by xCell\u003C\/strong\u003E\u003C\/p\u003E\u003Cp id=\u0022p-74\u0022\u003E\u003Cstrong\u003ETable S6. T cells abundance estimated by ImmunCellAI\u003C\/strong\u003E\u003C\/p\u003E\u003Cp id=\u0022p-75\u0022\u003E\u003Cstrong\u003ETable S7. Annotation of ctDNA somatic mutations\u003C\/strong\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ack\u0022 id=\u0022ack-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAcknowledgements\u003C\/h2\u003E\u003Cp id=\u0022p-54\u0022\u003EWe would like to thank Innovent Biologics, Inc for providing sintilimab for this study.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section fn-group\u0022 id=\u0022fn-group-1\u0022\u003E\u003Ch2\u003EFootnotes\u003C\/h2\u003E\u003Cul\u003E\u003Cli class=\u0022fn-update fn-group-summary-of-updates\u0022 id=\u0022fn-2\u0022\u003E\u003Cp id=\u0022p-21\u0022\u003ESection on whole RNA sequencing results updated to provide additional explanations and uploaded content; Notation format for multiple sampling time points revised to \u0027day X of cycle 1 (c1dX)\u0027; Calculation of pathological assessments updated to focus on the 31 patients who underwent surgery; Terminology and descriptions in the article revised.\n\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E1.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 1. in text\u0022 id=\u0022ref-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELiang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWakelee\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHA\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAdjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETransl Lung Cancer Res\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E2\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E403\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTransl%2BLung%2BCancer%2BRes%26rft.volume%253D2%26rft.spage%253D403%26rft_id%253Dinfo%253Apmid%252F25806259%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25806259\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E2.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-2-1\u0022 title=\u0022View reference 2. in text\u0022 id=\u0022ref-2\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EUramoto\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETanaka\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ERecurrence after surgery in patients with NSCLC\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETransl Lung Cancer Res\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E3\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E242\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTransl%2BLung%2BCancer%2BRes%26rft.volume%253D3%26rft.spage%253D242%26rft_id%253Dinfo%253Apmid%252F25806307%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25806307\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E3.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference 3. in text\u0022 id=\u0022ref-3\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.3\u0022 data-doi=\u002210.1016\/j.athoracsur.2012.03.031\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETaylor\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENagji\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBhamidipati\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETheodosakis\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKozower\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELau\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ETumor recurrence after complete resection for non-small cell lung cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Thorac Surg\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E93\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E6\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1813\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E20\u003C\/span\u003E; discussion 20-1.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DThe%2BAnnals%2Bof%2BThoracic%2BSurgery%26rft.stitle%253DAnn.%2BThorac.%2BSurg.%26rft.aulast%253DTaylor%26rft.auinit1%253DM.%2BD.%26rft.volume%253D93%26rft.issue%253D6%26rft.spage%253D1813%26rft.epage%253D1820%26rft.atitle%253DTumor%2Brecurrence%2Bafter%2Bcomplete%2Bresection%2Bfor%2Bnon-small%2Bcell%2Blung%2Bcancer.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.athoracsur.2012.03.031%26rft_id%253Dinfo%253Apmid%252F22542070%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.athoracsur.2012.03.031\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=22542070\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E4.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 4. in text\u0022 id=\u0022ref-4\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.4\u0022 data-doi=\u002210.1016\/j.jtho.2015.09.009\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGoldstraw\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChansky\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECrowley\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERami-Porta\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAsamura\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEberhardt\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EWE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EThe IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Thorac Oncol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E39\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E51\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ%2BThorac%2BOncol%26rft.volume%253D11%26rft.spage%253D39%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.jtho.2015.09.009%26rft_id%253Dinfo%253Apmid%252F26762738%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.jtho.2015.09.009\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26762738\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E5.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference 5. in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.5\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EGroup NM-aC\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPreoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E383\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9928\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1561\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E71\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E6.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6. in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EForde\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESpicer\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EProvencio\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMitsudomi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAwad\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ENeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E7.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7. in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERothschild\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESI\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZippelius\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEboulet\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEI\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESavic Prince\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBetticher\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBettini\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESAKK 16\/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Clin Oncol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E39\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E26\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2872\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E80\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ%2BClin%2BOncol%26rft.volume%253D39%26rft.spage%253D2872%26rft_id%253Dinfo%253Apmid%252F34251873%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=34251873\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E8.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-8-1\u0022 title=\u0022View reference 8. in text\u0022 id=\u0022ref-8\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.8\u0022 data-doi=\u002210.1016\/S1470-2045(20)30453-8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EProvencio\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENadal\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EInsa\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGarc\u00eda-Campelo\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECasal-Rubio\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ED\u00f3mine\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ENeoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EThe Lancet Oncology\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E21\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E11\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1413\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E22\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DThe%2BLancet%2BOncology%26rft.volume%253D21%26rft.spage%253D1413%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS1470-2045%252820%252930453-8%26rft_id%253Dinfo%253Apmid%252F32979984%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S1470-2045(20)30453-8\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=32979984\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E9.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference 9. in text\u0022 id=\u0022ref-9\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EForde\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESpicer\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EProvencio\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMitsudomi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAwad\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ENeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EThe New England journal of medicine\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E386\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E21\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1973\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E85\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E10.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-10-1\u0022 title=\u0022View reference 10. in text\u0022 id=\u0022ref-10\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.10\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGangopadhyay\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENath\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBiswas\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EReduced Dose Intensity of Chemotherapy may not Lead to Inferior Palliation in Locally Advanced Carcinoma of the Gall Bladder: An Experience from a Regional Cancer Centre in Eastern India\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Gastrointest Cancer\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E46\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E3\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E297\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E300\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ%2BGastrointest%2BCancer%26rft.volume%253D46%26rft.spage%253D297%26rft_id%253Dinfo%253Apmid%252F26116258%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26116258\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E11.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference 11. in text\u0022 id=\u0022ref-11\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.11\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECheng\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EDocetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Transl Med.\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E9\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E338\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAnn%2BTransl%2BMed.%26rft.volume%253D9%26rft.spage%253D338%26rft_id%253Dinfo%253Apmid%252F33708965%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=33708965\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E12.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 12. in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.12\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGui\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EReduced-dose post-transplant cyclophosphamide plus low-dose post-trans plant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical p eripheral blood stem cell transplantation: A multicentre, randomized c ontrolled clinical trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBr J Haematol\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E200\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E210\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E13.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference 13. in text\u0022 id=\u0022ref-13\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.13\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWinther\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELiposits\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESkuladottir\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHofsli\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShah\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPoulsen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELO\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EReduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Gastroenterol Hepatol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E376\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E88\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DLancet%2BGastroenterol%2BHepatol%26rft.volume%253D4%26rft.spage%253D376%26rft_id%253Dinfo%253Apmid%252F30852136%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=30852136\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E14.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference 14. in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.14\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYao\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhao\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGong\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EImpact of the combined timing of PD-1\/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EESMO Open\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E100094\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DESMO%2BOpen%26rft.volume%253D6%26rft.spage%253D100094%26rft_id%253Dinfo%253Apmid%252F33780892%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=33780892\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E15.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-15-1\u0022 title=\u0022View reference 15. in text\u0022 id=\u0022ref-15\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.15\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKidman\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPrincipe\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWatson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELassmann\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHolt\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENowak\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ECharacteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFront Immunol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E:\u003Cspan class=\u0022cit-issue\u0022\u003E587014\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E16.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-16-1\u0022 title=\u0022View reference 16. in text\u0022 id=\u0022ref-16\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.16\u0022 data-doi=\u002210.1158\/1078-0432.CCR-19-3418\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHellmann\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENabet\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERizvi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChaudhuri\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWells\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDunphy\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMPS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ECirculating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E12\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2849\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E58\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft_id%253Dinfo%253Adoi%252F10.1158%252F1078-0432.CCR-19-3418%26rft_id%253Dinfo%253Apmid%252F32046999%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6ImNsaW5jYW5yZXMiO3M6NToicmVzaWQiO3M6MTA6IjI2LzEyLzI4NDkiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNS8wNC8xNS8yMDI0LjA3LjExLjI0MzEwMTA1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E17.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-17-1\u0022 title=\u0022View reference 17. in text\u0022 id=\u0022ref-17\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.17\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGaudreau\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP-O\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENegrao\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMitchell\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EReuben\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECorsini\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ENeoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident M emory T Cell, and B Cell Infiltration in Resectable NSCLC\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of thoracic oncology : official publication of the Internation al Association for the Study of Lung Cancer\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E127\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E39\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E18.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-1\u0022 title=\u0022View reference 18. in text\u0022 id=\u0022ref-18\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.18\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGao\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECheng\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ECancer-cell-secreted CXCL11 promoted CD8\u003Csup\u003E+\u003C\/sup\u003E T cells infiltrat ion through docetaxel-induced-release of HMGB1 in NSCLC\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal for immunotherapy of cancer\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-issue\u0022\u003E42\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E19.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-19-1\u0022 title=\u0022View reference 19. in text\u0022 id=\u0022ref-19\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.19\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETopalian\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETaube\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPardoll\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDM\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ENeoadjuvant checkpoint blockade for cancer immunotherapy. Science (New York, NY)\u003C\/span\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E367\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E6477\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003Eeaax0182\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E20.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-20-1\u0022 title=\u0022View reference 20. in text\u0022 id=\u0022ref-20\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.20\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHuang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESOAPnuke: a MapReduce acceleration-supported software for integrated quality control and preprocessing of high-throughput sequencing data. (2047-217X (Electronic))\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E21.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-21-1\u0022 title=\u0022View reference 21. in text\u0022 id=\u0022ref-21\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.21\u0022 data-doi=\u002210.1186\/s12859-019-3280-9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhou\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHuang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELiao\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EXu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EGencore: an efficient tool to generate consensus reads for error suppressing and duplicate removing of NGS data\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBMC Bioinformatics\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E23\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E606\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBMC%2BBioinformatics%26rft.volume%253D20%26rft.spage%253D606%26rft_id%253Dinfo%253Adoi%252F10.1186%252Fs12859-019-3280-9%26rft_id%253Dinfo%253Apmid%252F31881822%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1186\/s12859-019-3280-9\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=31881822\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E22.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference 22. in text\u0022 id=\u0022ref-22\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.22\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDurbin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EFast and accurate short read alignment with Burrows-Wheeler transform. (1367-4811 (Electronic))\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E23.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-23-1\u0022 title=\u0022View reference 23. in text\u0022 id=\u0022ref-23\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.23\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDanecek\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBonfield\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELiddle\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMarshall\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EOhan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPollard\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMO\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ETwelve years of SAMtools and BCFtools\u003C\/span\u003E. LID - 10.1093\/gigascience\/giab008 [doi] LID - giab008. (2047-217X (Electronic)).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E24.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-24-1\u0022 title=\u0022View reference 24. in text\u0022 id=\u0022ref-24\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.24\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELai\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMarkovets\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAhdesmaki\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChapman\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHofmann\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EO\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMcEwen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EVarDict: a novel and versatile variant caller for next-generation sequ encing in cancer research\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENucleic acids research\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E44\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E11\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003Ee108\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E25.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-25-1\u0022 title=\u0022View reference 25. in text\u0022 id=\u0022ref-25\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.25\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECingolani\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPlatts\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECoon\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENguyen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EA program for annotating and predicting the effects of single nucleoti de polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaste r strain w1118; iso-2; iso-3\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFly (Austin)\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E80\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E92\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E26.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-1\u0022 title=\u0022View reference 26. in text\u0022 id=\u0022ref-26\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.26\u0022 data-doi=\u002210.1093\/bioinformatics\/bts635\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDobin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDavis\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchlesinger\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDrenkow\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZaleski\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJha\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESTAR: ultrafast universal RNA-seq aligner\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBioinformatics\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E29\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E15\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBioinformatics%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fbioinformatics%252Fbts635%26rft_id%253Dinfo%253Apmid%252F23104886%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/bioinformatics\/bts635\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23104886\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000312654600003\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E27.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-27-1\u0022 title=\u0022View reference 27. in text\u0022 id=\u0022ref-27\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.27\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDewey\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECN\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ERSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBMC Bioinformatics\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E:\u003Cspan class=\u0022cit-issue\u0022\u003E323\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E28.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-28-1\u0022 title=\u0022View reference 28. in text\u0022 id=\u0022ref-28\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.28\u0022 data-doi=\u002210\/gckmjs\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAran\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EButte\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAJ\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ExCell: digitally portraying the tissue cellular heterogeneity landscape\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EGenome Biology\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E18\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E220\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DGenome%2BBiology%26rft.volume%253D18%26rft.spage%253D220%26rft_id%253Dinfo%253Adoi%252F10%252Fgckmjs%26rft_id%253Dinfo%253Apmid%252F31601707%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10\/gckmjs\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=31601707\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E29.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-29-1\u0022 title=\u0022View reference 29. in text\u0022 id=\u0022ref-29\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.29\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMiao\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY-R\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELei\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELuo\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EXie\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG-Y\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAdv Sci (Weinh\u003C\/abbr\u003E).\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E7\u003C\/span\u003E):\u003Cspan class=\u0022cit-issue\u0022\u003E1902880\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E30.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-30-1\u0022 title=\u0022View reference 30. in text\u0022 id=\u0022ref-30\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.30\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBolotin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPoslavsky\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMitrophanov\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShugay\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMamedov\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPutintseva\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EMiXCR: software for comprehensive adaptive immunity profiling\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENature Methods\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E380\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNature%2BMethods%26rft.volume%253D12%26rft.spage%253D380%26rft_id%253Dinfo%253Apmid%252F25924071%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25924071\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E31.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-31-1\u0022 title=\u0022View reference 31. in text\u0022 id=\u0022ref-31\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.31\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERobinson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarker\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGeorgiou\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECooper\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFlicek\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMarsh\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESGE\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EIPD-IMGT\/HLA Database. (1362-4962 (Electronic))\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E32.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-32-1\u0022 title=\u0022View reference 32. in text\u0022 id=\u0022ref-32\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.32\u0022 data-doi=\u002210.1371\/journal.pcbi.1004503\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShugay\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBagaev\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETurchaninova\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBolotin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBritanova\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EOV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPutintseva\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EVDJtools: Unifying Post-analysis of T Cell Receptor Repertoires\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS Comput Biol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E11\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003Ee1004503\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPLoS%2BComput%2BBiol%26rft.volume%253D11%26rft.spage%253De1004503%26rft_id%253Dinfo%253Adoi%252F10.1371%252Fjournal.pcbi.1004503%26rft_id%253Dinfo%253Apmid%252F26606115%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1371\/journal.pcbi.1004503\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26606115\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E33.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-33-1\u0022 title=\u0022View reference 33. in text\u0022 id=\u0022ref-33\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.33\u0022 data-doi=\u002210.1158\/1078-0432.CCR-19-2931\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECaushi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEl Asmar\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAnagnostou\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECottrell\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ECompartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E6\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1327\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E37\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft_id%253Dinfo%253Adoi%252F10.1158%252F1078-0432.CCR-19-2931%26rft_id%253Dinfo%253Apmid%252F31754049%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6ImNsaW5jYW5yZXMiO3M6NToicmVzaWQiO3M6OToiMjYvNi8xMzI3IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjUvMDQvMTUvMjAyNC4wNy4xMS4yNDMxMDEwNS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E34.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2024.07.11.24310105v2.34\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhao\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJia\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EPeripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Transl Oncol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E23\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E8\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1646\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E56\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DClin%2BTransl%2BOncol%26rft.volume%253D23%26rft.spage%253D1646%26rft_id%253Dinfo%253Apmid%252F33583004%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=33583004\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E35.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-35-1\u0022 title=\u0022View reference 35. in text\u0022 id=\u0022ref-35\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.35\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EDiversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFront Immunol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E:\u003Cspan class=\u0022cit-issue\u0022\u003E649343\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E36.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-36-1\u0022 title=\u0022View reference 36. in text\u0022 id=\u0022ref-36\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.36\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHellmann\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPaz-Ares\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBernabe Caro\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZurawski\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKim\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES-W\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECarcereny Costa\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ENivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EThe New England journal of medicine\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E381\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E21\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2020\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E31\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E37.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-37-1\u0022 title=\u0022View reference 37. in text\u0022 id=\u0022ref-37\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.37\u0022 data-doi=\u002210.1002\/cncr.11882\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECrawford\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDale\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELyman\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGH\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EChemotherapy-induced neutropenia: risks, consequences, and new directions for its management\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2004\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E100\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E228\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E37\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DCancer%26rft.stitle%253DCancer%26rft.aulast%253DCrawford%26rft.auinit1%253DJ.%26rft.volume%253D100%26rft.issue%253D2%26rft.spage%253D228%26rft.epage%253D237%26rft.atitle%253DChemotherapy-induced%2Bneutropenia%253A%2Brisks%252C%2Bconsequences%252C%2Band%2Bnew%2Bdirections%2Bfor%2Bits%2Bmanagement.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fcncr.11882%26rft_id%253Dinfo%253Apmid%252F14716755%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1002\/cncr.11882\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=14716755\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000188610500004\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E38.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-38-1\u0022 title=\u0022View reference 38. in text\u0022 id=\u0022ref-38\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.38\u0022 data-doi=\u002210.1186\/s12916-022-02696-4\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESun\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESong\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHe\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EXie\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESafety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBMC Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E493\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBMC%2BMed%26rft.volume%253D20%26rft.spage%253D493%26rft_id%253Dinfo%253Adoi%252F10.1186%252Fs12916-022-02696-4%26rft_id%253Dinfo%253Apmid%252F36581917%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1186\/s12916-022-02696-4\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=36581917\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E39.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-39-1\u0022 title=\u0022View reference 39. in text\u0022 id=\u0022ref-39\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.39\u0022 data-doi=\u002210.1002\/1878-0261.13090\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003Evan der Leest\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHiddinga\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMiedema\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAguirre Azpurua\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EML\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERifaela\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETer Elst\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ECirculating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMol Oncol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E11\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2910\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E22\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DMol%2BOncol%26rft.volume%253D15%26rft.spage%253D2910%26rft_id%253Dinfo%253Adoi%252F10.1002%252F1878-0261.13090%26rft_id%253Dinfo%253Apmid%252F34449963%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1002\/1878-0261.13090\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=34449963\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E40.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-40-1\u0022 title=\u0022View reference 40. in text\u0022 id=\u0022ref-40\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.40\u0022 data-doi=\u002210.1158\/1078-0432.CCR-21-1200\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECasarrubios\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECruz-Bermudez\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENadal\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EInsa\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGarcia Campelo\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMDR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELazaro\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EPretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Cancer Res\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E27\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E21\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E5878\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E90\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DClin%2BCancer%2BRes%26rft_id%253Dinfo%253Adoi%252F10.1158%252F1078-0432.CCR-21-1200%26rft_id%253Dinfo%253Apmid%252F34376534%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6ImNsaW5jYW5yZXMiO3M6NToicmVzaWQiO3M6MTA6IjI3LzIxLzU4NzgiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNS8wNC8xNS8yMDI0LjA3LjExLjI0MzEwMTA1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E41.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-41-1\u0022 title=\u0022View reference 41. in text\u0022 id=\u0022ref-41\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.41\u0022 data-doi=\u002210.1056\/NEJMoa1716078\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EForde\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChaft\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAnagnostou\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECottrell\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHellmann\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ENeoadjuvant PD-1 Blockade in Resectable Lung Cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E378\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E21\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1976\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E86\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D378%26rft.spage%253D1976%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa1716078%26rft_id%253Dinfo%253Apmid%252F29658848%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMoa1716078\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=29658848\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F04%2F15%2F2024.07.11.24310105.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E42.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-42-1\u0022 title=\u0022View reference 42. in text\u0022 id=\u0022ref-42\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.42\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJiang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJiang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDong\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EUtilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETheranostics\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E257\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E67\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E43.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2024.07.11.24310105v2.43\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EProvencio\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESerna-Blasco\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENadal\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EInsa\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGarc\u00eda-Campelo\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECasal Rubio\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EOverall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of clinical oncology : official journal of the American Societ y of Clinical Oncology\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E40\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E25\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2924\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E33\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E44.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-44-1\u0022 title=\u0022View reference 44. in text\u0022 id=\u0022ref-44\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.07.11.24310105v2.44\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EXu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJiang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECheng\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ECamrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment f or Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of thoracic oncology : official publication of the Internation al Association for the Study of Lung Cancer\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-vol\u0022\u003E17\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E544\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E57\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_zP7WWIfzbyzvaM63L39cNV2juU_1XVH7wduFK9gcMNI.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}